73.05 USD
-0.08 (-0.11%)
73.05 USD
0 (0%)
Overall MIRM gets a fundamental rating of 4 out of 10. We evaluated MIRM against 533 industry peers in the Biotechnology industry. The financial health of MIRM is average, but there are quite some concerns on its profitability. MIRM shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year MIRM has reported negative net income.
In the past year MIRM had a positive cash flow from operations.
In the past 5 years MIRM always reported negative net income.
In the past 5 years MIRM reported 4 times negative operating cash flow.
1.2 Ratios
MIRM has a better Return On Assets (-5.30%) than 87.24% of its industry peers.
With an excellent Return On Equity value of -14.26%, MIRM belongs to the best of the industry, outperforming 87.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.3% | ||
| ROE | -14.26% | ||
| ROIC | N/A |
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MIRM's Gross Margin of 79.92% is amongst the best of the industry. MIRM outperforms 84.62% of its industry peers.
In the last couple of years the Gross Margin of MIRM has declined.
MIRM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
2. Health
2.1 Basic Checks
MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MIRM has more shares outstanding
Compared to 5 years ago, MIRM has more shares outstanding
Compared to 1 year ago, MIRM has an improved debt to assets ratio.
2.2 Solvency
MIRM has an Altman-Z score of 4.39. This indicates that MIRM is financially healthy and has little risk of bankruptcy at the moment.
MIRM's Altman-Z score of 4.39 is fine compared to the rest of the industry. MIRM outperforms 72.98% of its industry peers.
The Debt to FCF ratio of MIRM is 6.97, which is on the high side as it means it would take MIRM, 6.97 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MIRM (6.97) is better than 90.81% of its industry peers.
A Debt/Equity ratio of 1.06 is on the high side and indicates that MIRM has dependencies on debt financing.
MIRM has a worse Debt to Equity ratio (1.06) than 76.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | 6.97 | ||
| Altman-Z | 4.39 |
ROIC/WACCN/A
WACC8.35%
2.3 Liquidity
MIRM has a Current Ratio of 3.31. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
MIRM's Current ratio of 3.31 is on the low side compared to the rest of the industry. MIRM is outperformed by 60.23% of its industry peers.
MIRM has a Quick Ratio of 3.16. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
MIRM's Quick ratio of 3.16 is in line compared to the rest of the industry. MIRM outperforms 41.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.16 |
3. Growth
3.1 Past
MIRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.43%, which is quite impressive.
The Revenue has grown by 53.66% in the past year. This is a very strong growth!
The Revenue has been growing by 160.12% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
Revenue 1Y (TTM)53.66%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%
3.2 Future
Based on estimates for the next years, MIRM will show a very strong growth in Earnings Per Share. The EPS will grow by 31.65% on average per year.
The Revenue is expected to grow by 24.49% on average over the next years. This is a very strong growth
EPS Next Y62.39%
EPS Next 2Y41.69%
EPS Next 3Y39%
EPS Next 5Y31.65%
Revenue Next Year51.23%
Revenue Next 2Y34.62%
Revenue Next 3Y29.17%
Revenue Next 5Y24.49%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
MIRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 5115.55 indicates a quite expensive valuation of MIRM.
86.49% of the companies in the same industry are more expensive than MIRM, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of MIRM to the average of the S&P500 Index (36.59), we can say MIRM is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5115.55 |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MIRM indicates a rather cheap valuation: MIRM is cheaper than 91.74% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 84.54 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as MIRM's earnings are expected to grow with 39.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.69%
EPS Next 3Y39%
5. Dividend
5.1 Amount
MIRM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
73.05
-0.08 (-0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.48%
Inst Owner Change5.82%
Ins Owners1.88%
Ins Owner Change0.56%
Market Cap3.75B
Revenue(TTM)471.79M
Net Income(TTM)-41.63M
Analysts85.88
Price Target89.76 (22.87%)
Short Float %16.63%
Short Ratio10.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.86%
Min EPS beat(2)63.96%
Max EPS beat(2)129.77%
EPS beat(4)3
Avg EPS beat(4)26.25%
Min EPS beat(4)-99.42%
Max EPS beat(4)129.77%
EPS beat(8)4
Avg EPS beat(8)-5.65%
EPS beat(12)7
Avg EPS beat(12)-12.67%
EPS beat(16)10
Avg EPS beat(16)-42.14%
Revenue beat(2)2
Avg Revenue beat(2)8.03%
Min Revenue beat(2)0.25%
Max Revenue beat(2)15.82%
Revenue beat(4)4
Avg Revenue beat(4)7.03%
Min Revenue beat(4)0.25%
Max Revenue beat(4)15.82%
Revenue beat(8)7
Avg Revenue beat(8)4.34%
Revenue beat(12)11
Avg Revenue beat(12)8.01%
Revenue beat(16)13
Avg Revenue beat(16)3.12%
PT rev (1m)8.11%
PT rev (3m)25.12%
EPS NQ rev (1m)50.83%
EPS NQ rev (3m)54.82%
EPS NY rev (1m)0%
EPS NY rev (3m)38.61%
Revenue NQ rev (1m)-0.32%
Revenue NQ rev (3m)1.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)11.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5115.55 | ||
| P/S | 7.96 | ||
| P/FCF | 84.54 | ||
| P/OCF | 83.87 | ||
| P/B | 12.85 | ||
| P/tB | 62.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.86
EYN/A
EPS(NY)0.01
Fwd EY0.02%
FCF(TTM)0.86
FCFY1.18%
OCF(TTM)0.87
OCFY1.19%
SpS9.18
BVpS5.68
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.3% | ||
| ROE | -14.26% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.92% | ||
| FCFM | 9.41% |
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | 6.97 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.46% | ||
| Cap/Sales | 0.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.16 | ||
| Altman-Z | 4.39 |
F-Score6
WACC8.35%
ROIC/WACCN/A
Cap/Depr(3y)94.39%
Cap/Depr(5y)705.48%
Cap/Sales(3y)5.79%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
EPS Next Y62.39%
EPS Next 2Y41.69%
EPS Next 3Y39%
EPS Next 5Y31.65%
Revenue 1Y (TTM)53.66%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%
Revenue Next Year51.23%
Revenue Next 2Y34.62%
Revenue Next 3Y29.17%
Revenue Next 5Y24.49%
EBIT growth 1Y56.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.43%
EBIT Next 3Y45.06%
EBIT Next 5YN/A
FCF growth 1Y142.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y150.52%
OCF growth 3YN/A
OCF growth 5YN/A
MIRUM PHARMACEUTICALS INC / MIRM FAQ
What is the fundamental rating for MIRM stock?
ChartMill assigns a fundamental rating of 4 / 10 to MIRM.
What is the valuation status of MIRUM PHARMACEUTICALS INC (MIRM) stock?
ChartMill assigns a valuation rating of 3 / 10 to MIRUM PHARMACEUTICALS INC (MIRM). This can be considered as Overvalued.
Can you provide the profitability details for MIRUM PHARMACEUTICALS INC?
MIRUM PHARMACEUTICALS INC (MIRM) has a profitability rating of 3 / 10.